Background

Evaluation of preoperative clinical and translational selection criteria for cytoreductive surgery in endometrial cancer. A retrospective multicenter study with an accompanying translational project.

Indication

Advanced or recurrent endometrial cancer

Study design

European, open, retrospective, descriptive, non-interventional, multicenter study

Target group

Adult patients who have undergone cytoreductive surgery for advanced endometrial cancer with peritoneal metastases (FIGO IV) or for recurrent endometrial cancer at European cancer centers.

Goals

To develop hypotheses and specific selection criteria based on clinical and/or translational features to identify patients most likely to benefit from radical cytoreduction, i.e., complete resection, which could serve as the basis for future prospective studies on cytoreductive surgery for endometrial cancer.

Primary goal

Identification of clinical selection criteria for predicting complete cytoreduction in patients with advanced or recurrent endometrial cancer.

Secondary goals

Clinical part:

• Evaluation of prognostic factors predicting the benefit of cytoreductive surgery in advanced or recurrent endometrial cancer
• Identification of prognostic markers for clinical outcome

Translational part:

• Evaluation of the predictive value of TCGA molecular classification for surgical outcome in endometrial cancer
• Identification of biological and molecular expression profiles predicting complete cytoreduction in patients with endometrial cancer and their prognostic significance

Exploratory goals

Description of current treatment practices in participating European countries for advanced or recurrent endometrial cancer

Recruitment

Patient recruitment will be competitive across multiple sites and ENGOT study groups. It is planned to activate approximately 69 sites in twelve countries. According to feasibility questionnaires, a total of approximately 1400 patients are expected.

Duration of study

The data and sample collection of the retrospective cases took place between January 2011 and December 2020, covering a total period of 18 months.

The Swiss GO Trial Group represents the Swiss participation in the study (Swiss-GO-11). A total of 12 sites are participating in the study.

For further information please contact the Swiss GO Trial Group at: This email address is being protected from spambots. You need JavaScript enabled to view it.

Thank you!

AGO-OP.11/ ENGOTen22/ STREAM